RemeGen Co. Ltd. Class A

As of December 31, 2025, Remegen Co Ltd. carries a market capitalization of 9.89B, placing it among publicly traded companies globally. Its enterprise value stands at 9.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Remegen Co Ltd.'s next confirmed earnings release is scheduled for October 29, 2026.

As of December 31, 2025, Remegen Co Ltd. has 1.01B shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Remegen Co Ltd. maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on September 18, 2026, Remegen Co Ltd.'s stock has gained approximately 96.84% over the past 52 weeks.

As of December 31, 2025, Remegen Co Ltd. holds 338.95M in cash and equivalents against 314.86M in total debt, resulting in a net debt position of 143.58M. Total book value stands at 516.09M, with working capital of 170.12M providing operational flexibility.